AEON Biopharma Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.
Date: March 29, 2024
| | | |
|---|---|---|
| | AEON BIOPHARMA, INC. | |
| | | |
| | By: | /s/ Marc Forth |
| | Name: | Marc Forth |
| | Title: | President, Chief Executive Officer |
| | | |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Marc Forth and Peter Reynolds as such individual’s true and lawful attorney in fact and agent with full power of substitution, for such individual in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney in fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney in fact, proxy and agent, or the individual’s substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| | | | | |
|---|---|---|---|---|
| Signature | | Title | | Date |
| | | | ||
| /s/ Marc Forth | | President, Chief Executive Officer and Director | | March 29, 2024 |
| Marc Forth | | (Principal Executive Officer) | | |
| | | | | |
| /s/ Peter Reynolds | | Chief Financial Officer | | March 29, 2024 |
| Peter Reynolds | | (Principal Financial Officer and Principal Accounting Officer) | | |
| | | | | |
| /s/ Jost Fischer | | Chairman of the Board | | March 29, 2024 |
| Jost Fischer | | | | |
| | | | | |
| /s/ Shelley Thunen | | Director | | March 29, 2024 |
| Shelley Thunen | | | | |
| | | | | |
| /s/ Robert Palmisano | | Director | | March 29, 2024 |
| Robert Palmisano | | | | |
| | | | | |
| /s/ Eric Carter | | Director | | March 29, 2024 |
| Eric Carter | | | | |
| | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.